PE20200793A1 - Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprenden - Google Patents
Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprendenInfo
- Publication number
- PE20200793A1 PE20200793A1 PE2020000027A PE2020000027A PE20200793A1 PE 20200793 A1 PE20200793 A1 PE 20200793A1 PE 2020000027 A PE2020000027 A PE 2020000027A PE 2020000027 A PE2020000027 A PE 2020000027A PE 20200793 A1 PE20200793 A1 PE 20200793A1
- Authority
- PE
- Peru
- Prior art keywords
- nitrogen
- phenyl
- ring
- rip1 kinase
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Se refiere un compuesto de formula (l) o sales farmaceuticamente aceptables del mismo, en donde R1 se selecciona entre alquilo C1-C6, cicloalquilo C3-C6, alcoxi C1-C6, entre otros; el anillo A es un heteroarilo de 5 miembros que tiene como unicos heteroatomos, (i) dos o tres atomos de nitrogeno, (ii) un atomo de nitrogeno y oxigeno, o (iii) un atomo de nitrogeno y azufre; en donde el anillo A esta unido al carbonilo adyacente mediante un atomo de carbono; y el anillo B es un cicloalquilo de 4 a 8 miembros, o un heterociclilo de 4 a 8 miembros que tiene de 1 a 3 heteroatomos seleccionados entre el grupo que consiste en nitrogeno, oxigeno y azufre. Son compuestos preferidos: ((5S,7S)-7-fluoro-5-fenil-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-il)((1R,2R)-2-fluorociclopropil)metanona; 2-fenil-1-[rac-(5S,7S)-7-fluoro-5-fenil-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-il]etanona; entre otros. Dichos compuestos tienen una actividad inhibidora de RIP1 quinasa Ki de menos de 100 nM, siendo utiles en el tratamiento de una enfermedad o un trastorno como la enfermedad de Parkinson, demencia con cuerpos de Lewy, atrofia de multiples sistemas, entre otros. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto y a un metodo de tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532767P | 2017-07-14 | 2017-07-14 | |
| PCT/EP2018/068998 WO2019012063A1 (en) | 2017-07-14 | 2018-07-12 | BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200793A1 true PE20200793A1 (es) | 2020-08-10 |
Family
ID=62916677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000027A PE20200793A1 (es) | 2017-07-14 | 2018-07-12 | Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprenden |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11098058B2 (es) |
| EP (2) | EP3652178B1 (es) |
| JP (2) | JP7258843B2 (es) |
| KR (2) | KR20240065201A (es) |
| CN (2) | CN119613408A (es) |
| AR (1) | AR112274A1 (es) |
| AU (3) | AU2018300043B2 (es) |
| BR (1) | BR112020000771A2 (es) |
| CA (2) | CA3067944C (es) |
| CL (1) | CL2020000101A1 (es) |
| CO (1) | CO2020000134A2 (es) |
| CR (1) | CR20200002A (es) |
| DK (1) | DK3652178T3 (es) |
| ES (1) | ES2973661T3 (es) |
| FI (1) | FI3652178T3 (es) |
| HR (1) | HRP20240354T1 (es) |
| HU (1) | HUE065793T2 (es) |
| IL (2) | IL271981B (es) |
| LT (1) | LT3652178T (es) |
| MA (1) | MA49560B1 (es) |
| PE (1) | PE20200793A1 (es) |
| PH (1) | PH12020500105A1 (es) |
| PL (1) | PL3652178T3 (es) |
| PT (1) | PT3652178T (es) |
| RS (1) | RS65308B1 (es) |
| SG (1) | SG11202000333UA (es) |
| SI (1) | SI3652178T1 (es) |
| TW (1) | TWI805595B (es) |
| UA (1) | UA125448C2 (es) |
| WO (1) | WO2019012063A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| PT3652178T (pt) | 2017-07-14 | 2024-03-18 | H Hoffnabb La Roche Ag | Compostos bicíclicos de cetona e métodos de utilização dos mesmos |
| CR20200168A (es) | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
| WO2020146615A1 (en) * | 2019-01-11 | 2020-07-16 | Genentech, Inc. | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| KR20220162155A (ko) | 2020-04-27 | 2022-12-07 | 주식회사 오토텍바이오 | Ubr 박스 도메인 리간드로의 화합물 |
| MX2023011482A (es) * | 2021-04-02 | 2023-10-03 | Genentech Inc | Proceso para preparar compuestos de cetona biciclicos. |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
| PE20250162A1 (es) * | 2022-05-19 | 2025-01-22 | Merck Sharp And Dohme Llc | Inhibidores de ripk1 y metodos de uso |
| WO2024260932A2 (en) * | 2023-06-19 | 2024-12-26 | F. Hoffmann-La Roche Ag | Process for the preparation of a chiral pyrrolo triazole alcohol |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| WO1998056376A1 (en) | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
| CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7514441B2 (en) | 2002-08-26 | 2009-04-07 | Takeda Pharmaceutical Company Limited | Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| ES2314418T3 (es) | 2003-05-02 | 2009-03-16 | Elan Pharmaceuticals, Inc. | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. |
| EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
| WO2006114706A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| AR077463A1 (es) | 2009-07-09 | 2011-08-31 | Irm Llc | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
| BR112014010391A2 (pt) | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| CA2871695A1 (en) | 2012-05-22 | 2013-11-28 | F. Hoffmann-La Roche Ag | Substituted dipyridylamines and uses thereof |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| KR20160002850A (ko) | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
| PE20161063A1 (es) | 2013-05-01 | 2016-10-22 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
| CA2917198C (en) | 2013-07-10 | 2022-06-07 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CN107406462B (zh) | 2015-03-09 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 三环dlk抑制剂及其用途 |
| JP6785252B2 (ja) * | 2015-07-02 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ラクタム及びその使用方法 |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MY196648A (en) | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3566471B1 (en) | 2017-01-05 | 2022-09-28 | Microsoft Technology Licensing, LLC | Audio simulation in video games comprising indirect propagation paths |
| PT3652178T (pt) | 2017-07-14 | 2024-03-18 | H Hoffnabb La Roche Ag | Compostos bicíclicos de cetona e métodos de utilização dos mesmos |
| MX2020003439A (es) | 2017-10-11 | 2020-07-29 | Hoffmann La Roche | Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1). |
| CR20200168A (es) | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
-
2018
- 2018-07-12 PT PT187408158T patent/PT3652178T/pt unknown
- 2018-07-12 FI FIEP18740815.8T patent/FI3652178T3/fi active
- 2018-07-12 AR ARP180101941 patent/AR112274A1/es active IP Right Grant
- 2018-07-12 IL IL271981A patent/IL271981B/en unknown
- 2018-07-12 DK DK18740815.8T patent/DK3652178T3/da active
- 2018-07-12 MA MA49560A patent/MA49560B1/fr unknown
- 2018-07-12 PE PE2020000027A patent/PE20200793A1/es unknown
- 2018-07-12 SG SG11202000333UA patent/SG11202000333UA/en unknown
- 2018-07-12 CN CN202411725301.0A patent/CN119613408A/zh active Pending
- 2018-07-12 UA UAA202000831A patent/UA125448C2/uk unknown
- 2018-07-12 ES ES18740815T patent/ES2973661T3/es active Active
- 2018-07-12 EP EP18740815.8A patent/EP3652178B1/en active Active
- 2018-07-12 KR KR1020247014915A patent/KR20240065201A/ko active Pending
- 2018-07-12 SI SI201831080T patent/SI3652178T1/sl unknown
- 2018-07-12 LT LTEPPCT/EP2018/068998T patent/LT3652178T/lt unknown
- 2018-07-12 CA CA3067944A patent/CA3067944C/en active Active
- 2018-07-12 CN CN201880046714.2A patent/CN110914271B/zh active Active
- 2018-07-12 EP EP24152498.2A patent/EP4397309A3/en active Pending
- 2018-07-12 IL IL294961A patent/IL294961A/en unknown
- 2018-07-12 US US16/034,207 patent/US11098058B2/en active Active
- 2018-07-12 KR KR1020207004030A patent/KR102664604B1/ko active Active
- 2018-07-12 HR HRP20240354TT patent/HRP20240354T1/hr unknown
- 2018-07-12 PL PL18740815.8T patent/PL3652178T3/pl unknown
- 2018-07-12 JP JP2020501256A patent/JP7258843B2/ja active Active
- 2018-07-12 TW TW107124048A patent/TWI805595B/zh active
- 2018-07-12 WO PCT/EP2018/068998 patent/WO2019012063A1/en not_active Ceased
- 2018-07-12 AU AU2018300043A patent/AU2018300043B2/en active Active
- 2018-07-12 BR BR112020000771-4A patent/BR112020000771A2/pt unknown
- 2018-07-12 CA CA3185865A patent/CA3185865A1/en active Pending
- 2018-07-12 CR CR20200002A patent/CR20200002A/es unknown
- 2018-07-12 RS RS20240314A patent/RS65308B1/sr unknown
- 2018-07-12 HU HUE18740815A patent/HUE065793T2/hu unknown
-
2020
- 2020-01-08 CO CONC2020/0000134A patent/CO2020000134A2/es unknown
- 2020-01-13 CL CL2020000101A patent/CL2020000101A1/es unknown
- 2020-01-14 PH PH12020500105A patent/PH12020500105A1/en unknown
-
2021
- 2021-01-12 US US17/147,449 patent/US11834461B2/en active Active
- 2021-06-26 AU AU2021204369A patent/AU2021204369A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061174A patent/JP7734163B2/ja active Active
- 2023-05-25 AU AU2023203292A patent/AU2023203292B2/en active Active
- 2023-11-21 US US18/516,014 patent/US20240300974A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200793A1 (es) | Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprenden | |
| PE20212250A1 (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria sobre cdk2 | |
| ECSP21012498A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CL2020002748A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20091349A1 (es) | Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| CL2009000619A1 (es) | Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer. | |
| MY197116A (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| EA201890473A1 (ru) | Гетероарильные производные в качестве ингибиторов parp | |
| NI201200059A (es) | PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS | |
| ECSP15029636A (es) | Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| MX380799B (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| PE20190968A1 (es) | Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih | |
| BR112016007016A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica | |
| CO2017000980A2 (es) | Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a) | |
| AR080871A1 (es) | Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| MX382128B (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| MX2019010169A (es) | Compuestos novedosos utiles como abridores del canal de potasio. |